Evidence map›Paper›PMID 41941258›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2026

Genitourinary malignancy among patients presenting with microscopic hematuria in Northwestern Ontario.

Shahrzad Keramati, Ahmed Mousa, Moustafa Fathy, Vahid Mehrnoush, Mark Tatangelo, Neda Ghaffarimarandi, Salima Oukachbi, Mohammed Bassuony, Farah Labib, Dina S Shaker and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shahrzad KeramatiNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Ahmed MousaNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Moustafa FathyNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Vahid MehrnoushNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Mark TatangeloNorthern Ontario School of Medicine, Sudbury, ON, Canada.
Neda GhaffarimarandiNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Salima OukachbiNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Mohammed BassuonyNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Farah LabibNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Dina S ShakerBenha University, Al Qalyubiyah, Egypt.
Abdalla BazazoNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Ahmed S ZakariaNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.
Ahmed KotbUniversity of Alberta, Grande Prairie, AB, Canada.
Kristen MorinNorthern Ontario School of Medicine, Sudbury, ON, Canada.
David MarshNorthern Ontario School of Medicine, Sudbury, ON, Canada.
Hazem ElmansyNorthern Ontario School of Medicine, Thunder Bay, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMicroscopic hematuria (MH) may indicate an underlying genitourinary (GU) malignancy. Accordingly, MH workup is essential to mitigate GU cancer-related morbidity and mortality. This study aimed to evaluate the etiologies of MH in Northwestern Ontario, Canada.

methodsWe conducted a retrospective cohort chart review of 2545 patients referred to our institution for MH from 2010-2020. Demographic and clinical data were collected. Low- and high-grade MH were defined as ≤25 and >25 red blood cells (RBCs) per high-power field (HPF), respectively.

resultsThe prevalence of GU cancer was 5.2% among patients with MH; the majority of cases (108/133, 81.2%) were identified during the initial workup, with urothelial carcinoma of the bladder being the most common subtype (81.2%). GU cancer was significantly associated with male sex (odds ratio [OR] 2.958, p<0.001), older age (OR 1.033, p<0.001), history of gross hematuria (GH) occurring more than 12 months prior (OR 3.469, p<0.001), prior lower urinary tract symptoms (LUTS, OR 0.081, p=0.014), and high-grade MH (>25 RBC/HPF, OR 2.977, p<0.001). High-grade GU cancer was significantly associated with male sex (OR 3.012, p<0.001), older age (OR 1.033, p<0.001), prior GH (OR 4.195, p<0.001), and history of LUTS (OR 0.088, p=0.016).

conclusionsIn our cohort, the prevalence of GU malignancy among patients with MH was 5.2%. Significant associations were observed with male sex, older age, and prior GH. High-grade MH was linked to increased GU cancer risk, emphasizing the importance of followup even in patients with low-grade MH, with prioritization given to those with high-grade MH.

Identifiers

PMID41941258
PMCPMC13423281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.